FDA approves first gene-editing treatment for human illness
In a landmark decision, the Food and Drug Administration Friday approved the first gene-editing treatment to alleviate human illness.
The FDA approved two gene therapies for anyone 12 and older suffering from the most severe form of sickle cell disease, a brutal blood disorder that has long been neglected by medical research.
The decisions are being hailed as milestones for treating sickle cell and for the rapidly advancing field of gene therapy, which is stirring excitement for treatment of many diseases.
"Sickle cell disease is a rare, debilitating and life-threatening blood disorder with significant unmet need, and we are excited to advance the field especially for individuals whose lives have been severely disrupted by the disease by approving two cell-based gene therapies today," said Dr. Nicole Verdun, director of the
You’re reading a preview, subscribe to read more.
Start your free 30 days